Memory Care Living Reinvents Alzheimer's and Dementia Care
RAMSEY, N.J., Sept. 1, 2015 /PRNewswire/ -- Memory Care Living is reinventing the way Alzheimer's disease and dementia care is practiced. Some symptoms of Alzheimer's disease and other types of dementia are forgetfulness, aggression, delusions and wandering. The industry standard is to administer anti-psychotic drugs to alleviate symptoms of the disease.
Memory Care Living is moving away from using anti-psychotic drugs and instead uses behavioral tracking to meet the needs of residents. Memory Care Living has 13 communities throughout New Jersey.
Cheryl Salo, house leader for Memory Care Living, works with residents daily.
"Memory Care Living's goal is to increase the cognitive and physical activity of our residents. We learn about our residents and track actions to find the reason behind their challenging behaviors without resorting to antipsychotics," Salo said.
In 2005, The FDA issued a public health advisory to alert health care providers and patients about increased mortality associated with anti-psychotic drugs used by patients with dementia.
Despite the warning, a 2015 Danish psychotropic drug study suggests over 75 percent of patients with dementia are treated with anti-psychotic medications.
The move away from institutionalized care is new to the senior healthcare industry. Memory Care Living is a leading provider of elder care, focusing specifically on Alzheimer's disease and dementia. The company emphasizes personalizing the care for each resident.
For more information, contact Elissia Gobencion, Director of Communication at [email protected] or 201-615-5954.
SOURCE Memory Care Living
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article